Imudon (polyvalent bacterial lysate)

Imudon (polyvalent bacterial lysate) is evaluated for the following indications with varying evidence strength: Immune support and respiratory infection care (evidence tier F), Chronic tonsillitis and pharyngitis (evidence tier F), Prevention of recurrent respiratory infections (evidence tier F). See the full indication matrix with dosing and citations above on this page.

Common side effects of Imudon (polyvalent bacterial lysate) (≥ 1 in 100): Per manufacturer label: rare allergic reactions, nausea, abdominal pain. See the Safety section for uncommon and serious reactions.

FDA category N. Pregnancy data are limited. International sources provide no recommendations.

Imudon is a lysate of 13 oral bacterial species formulated as oral lozenges. The manufacturer (Solvay/Abbott) withdrew from the Russian market; the product is not registered in Spain. No systematic reviews confirm clinical benefit in stomatitis or tonsillitis. No data exist on the transfer of lysate components into human milk; systemic absorption is presumed minimal. Routine use during breastfeeding is not supported.

Imudon (polyvalent bacterial lysate) is contraindicated in: Hypersensitivity to any component; Autoimmune diseases (per label, with caution). Full list in the Safety section.

unlike registered vaccines (pneumococcal, Haemophilus, influenza), Imudon bacterial lysates have not undergone phased clinical trials assessing clinical outcomes – tonsillitis frequency, tonsillectomies, hospitalisations. Claims of 'training local immunity' remain hypothetical.